DiNardo, Courtney D. http://orcid.org/0000-0001-9003-0390
Hochhaus, Andreas
Frattini, Mark G.
Yee, Karen
Zander, Thomas
Krämer, Alwin
Chen, Xueying
Ji, Yan
Parikh, Nehal S.
Choi, Joanne
Wei, Andrew H.
Clinical trials referenced in this document:
Documents that mention this clinical trial
A phase 1 study of IDH305 in patients with IDH1R132-mutant acute myeloid leukemia or myelodysplastic syndrome
https://doi.org/10.1007/s00432-022-03983-6
Funding for this research was provided by:
Novartis
Article History
Received: 2 February 2022
Accepted: 10 March 2022
First Online: 30 March 2022
Declarations
:
: CDD: CDD received research funding from AbbVie, Agios, Calithera, Cleave, BMS/Celgene, Daiichi-Sankyo, Forma, ImmuneOnc, Loxo, and received consultancy or advisory board fees from AbbVie, Agios, Aprea, Celgene/BMS, ImmuneOnc, Novartis, and Takeda. AH: research support from BMS, Incyte, Novartis, Pfizer. MGF: research support from Abbvie and Tolero Pharmaceuticals; current employment and equity ownership at Cellectis Inc. NY. KY: research funding from Agensys, Astex, Forma Therapeutics, Genentech, Jazz, Medimmune, Novartis, Onconova, Roche, and Honoraria from Celgene/BMS, Novartis, Otsuka Pfizer, TaiHo, Takeda. TZ: other support from BMS, MSD, Novartis, Roche. AK: Grants from Celgene, Daiichi Sankyo, Roche, and personal fees from Abbvie, BMS, Daiichi Sankyo, Roche. XC: employee of Novartis. YJ: employee of Novartis. NSP: employee of Novartis at time of study conduct and manuscript writing. JC: employee of Novartis. AHW: honoraria from Novartis, Astellas, Pfizer, Macrogenics, AbbVie, Genentech, Servier, Celgene, Amgen, Astra Zeneca and Janssen; research funding from Novartis, Celgene, AbbVie, Servier, Astra Zeneca and Amgen; former employee of the Walter and Eliza Hall Institute and receives a fraction of its royalty stream related to venetoclax.
: The study protocol was approved by the independent ethics committee or institutional review board for each center. The study was conducted according to the principles of the Declaration of Helsinki, and performed in compliance with Good Clinical Practice.
: All the patients provided written informed consent before participation in the clinical trial.
: All the authors have read and approved the final manuscript for submission to “Journal of Cancer Research and Clinical Oncology”.